Pancreatic Cancer Research

Clinical trialPhase 2Unknown

Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

A Prospective, One-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Investigator-selected Chemotherapy for Second-line Treatment of Advanced or Metastatic Pancreatic Cancer: a

Outcome
Outcome unknown
Phase
Phase 2
Status
Unknown
Study type
Interventional
Start
1 January 2023
Listed end
30 June 2025
Enrollment
30 participants
Sites
1
Primary outcomes
MedianProgression free survival(mPFS)
Sponsor type
Academic / other
Results posted
No
Last update
9 June 2023

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a prospective, one-arm, phase II clinical study of Tislelizumab Combined With Anlotinib and Chemotherapy for Second-line Treatment of Advanced or Metastatic Pancreatic Cancer

Detailed description public domain (ClinicalTrials.gov)

This is a single-arm, open-label, clinical trial of tislelizumab in combination with anlotinib and investigator-selected chemotherapy for second-line treatment of patients with advanced or metastatic pancreatic cancer. Patients with histopathologically or cytologically confirmed unresectable, recurrent or metastatic pancreatic cancer are planned to be recruited. Systemic medical antineoplastic therapy previously treated with first-line chemotherapy, meeting the inclusion and exclusion criteria of this study, and giving tislelizumab and anlotinib in combination with investigator 's choice of second-line chemotherapy regimen